NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect

Herein, we investigated therapeutic potential of a novel histone lysine demethylase 1 (LSD1) inhibitor, NCL1, in prostate cancer. Hormone-sensitive prostate cancer cells, (LNCaP) and castration resistant cancer cells (PC3 and PCai1) were treated with NCL1, and LSD1 expression and cell viability were...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncotarget
Prif Awduron: Etani, Toshiki, Suzuki, Takayoshi, Naiki, Taku, Naiki-Ito, Aya, Ando, Ryosuke, Iida, Keitaro, Kawai, Noriyasu, Tozawa, Keiichi, Miyata, Naoki, Kohri, Kenjiro, Takahashi, Satoru
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2014
Pynciau:
Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4413623/
https://ncbi.nlm.nih.gov/pubmed/25605246
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg